Exploring Iron Death in Tumor Microenvironment Around Glutathione Depletion and Its Application

Iron death represents a nuanced area of exploration within the realm of regulatory cell death (RCD), distinguished by its reliance on iron-mediated lipid peroxidation, setting it apart from conventional cell death pathways like apoptosis and necrosis. This process is hallmarked by an overload of intracellular iron and the accumulation of reactive oxygen species (ROS) due to unchecked lipid peroxidation, leading to cellular demise. The dual nature of iron death in cancer progression acting both as a facilitator and inhibitor of tumor growth underscores its complexity and the need for a deeper understanding of its molecular underpinnings. In the context of cancer biology, iron death's interaction with the tumor microenvironment (TME) and its impact on immune responses, particularly involving CD8+ T cells, have garnered significant attention. This form of cell death has been implicated in shaping the immune landscape within tumors, influencing the efficacy of cancer immunotherapies. Its potential to either promote or hinder carcinogenesis depending on the specific cancer type and stage highlights the intricate balance that exists. The review aims to consolidate current knowledge on the pivotal mechanisms governing iron death, emphasizing its regulation and the dichotomy of its roles in cancer development. By examining how iron death can either drive or suppress tumorigenesis across various human malignancies, the text seeks to elucidate the factors that determine this outcome. Furthermore, it catalogues a range of pharmacological agents capable of inducing iron death, shedding light on their therapeutic potential and the future prospects of leveraging targeted iron death induction as a novel strategy in cancer treatment. Through this synthesis, the review contributes to our comprehension of iron death's multifaceted involvement in cancer pathophysiology and its untapped potential for clinical intervention.